These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 16942119)

  • 1. Accuracy versus transparency in pharmacoeconomic modelling: finding the right balance.
    Eddy DM
    Pharmacoeconomics; 2006; 24(9):837-44. PubMed ID: 16942119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
    Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
    Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Achieving Appropriate Model Transparency: Challenges and Potential Solutions for Making Value-Based Decisions in the United States.
    Carlson JJ; Walton SM; Basu A; Chapman RH; Campbell JD; McQueen RB; Pearson SD; Touchette DR; Veenstra D; Whittington MD; Ollendorf DA
    Pharmacoeconomics; 2019 Nov; 37(11):1321-1327. PubMed ID: 31485925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Children's questions: a mechanism for cognitive development.
    Chouinard MM
    Monogr Soc Res Child Dev; 2007; 72(1):vii-ix, 1-112; discussion 113-26. PubMed ID: 17394580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of different uncertainty techniques in urban stormwater quantity and quality modelling.
    Dotto CB; Mannina G; Kleidorfer M; Vezzaro L; Henrichs M; McCarthy DT; Freni G; Rauch W; Deletic A
    Water Res; 2012 May; 46(8):2545-58. PubMed ID: 22402270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can You Repeat That? Exploring the Definition of a Successful Model Replication in Health Economics.
    McManus E; Turner D; Sach T
    Pharmacoeconomics; 2019 Nov; 37(11):1371-1381. PubMed ID: 31531833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--7.
    Eddy DM; Hollingworth W; Caro JJ; Tsevat J; McDonald KM; Wong JB;
    Value Health; 2012; 15(6):843-50. PubMed ID: 22999134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mathematical modelling and prediction in infectious disease epidemiology.
    Huppert A; Katriel G
    Clin Microbiol Infect; 2013 Nov; 19(11):999-1005. PubMed ID: 24266045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The generalisability of pharmacoeconomic studies.
    Mason J
    Pharmacoeconomics; 1997 Jun; 11(6):503-14. PubMed ID: 10168092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A guideline for the use of pharmacoeconomic models of diabetes treatment in the US managed-care environment.
    Veenstra DL; Ramsey SD; Sullivan SD
    Pharmacoeconomics; 2002; 20 Suppl 1():21-30. PubMed ID: 12036381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Configural and featural discriminations use the same spatial frequencies: a model observer versus human observer analysis.
    Collin CA; Rainville S; Watier N; Boutet I
    Perception; 2014; 43(6):509-26. PubMed ID: 25154285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7.
    Eddy DM; Hollingworth W; Caro JJ; Tsevat J; McDonald KM; Wong JB;
    Med Decis Making; 2012; 32(5):733-43. PubMed ID: 22990088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Addiction and brief-systemic therapy: working with compulsion].
    Cottencin O; Doutrelugne Y; Goudemand M; Consoli SM
    Encephale; 2009 Jun; 35(3):214-9. PubMed ID: 19540406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What Do Different Evaluation Metrics Tell Us About Saliency Models?
    Bylinskii Z; Judd T; Oliva A; Torralba A; Durand F
    IEEE Trans Pattern Anal Mach Intell; 2019 Mar; 41(3):740-757. PubMed ID: 29993800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacoeconomics and formulary decision making.
    Sanchez LA
    Pharmacoeconomics; 1996; 9 Suppl 1():16-25. PubMed ID: 10160112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.